Shenzhen Nexconn Pharmatechs Ltd

active pharmaceutica(2)
nexconn(1)

Showing 1 - 3 of 3, total 1 pages [First] [Previous] [Next] [Last]

dabigatran etexilate mesylate
Specification: 99%+ purity, unknown single impurity<0.1%
Detail: Dabigatran etexilate mesylate was first approved by EMA on May 18,2008, then approved by the USA FDA on Oct 19,2010, and approved by P*** on Jan 21,2011. It was developed and marketed as Pradaxa by Boehringer Ingelheim in DE a...

rivaroxaban
Specification: 99%+ purity, unknown single impurity<0.1%
Detail: Rivaroxaban was first approved by Health Canada on September 15, 2008, then approved by European Medicine Agency£¨EMA£©on September 30, 2008, and approved by the US Food and Drug Administration£¨FDA£© on July 01,2011. It was d...

lenalidomide
Specification: 99%+ purity, unknown single impurity<0.1%
Detail: Lenalidomide was first approved by the US FDA on Dec 27,2005, then approved by EMA on June 14,2007. It was developed and marketed as Revlimid by Celgene. Lenalidomide is an analogue of thalidomide with immunomodulatory, antian...


Showing 1 - 3 of 3, total 1 pages [First] [Previous] [Next] [Last]
1